Toll Free: 1-888-928-9744

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 102 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2016', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 9 Therapeutics Development 10 Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 10 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 18 3SBio Inc. 18 Amgen Inc. 19 Baxalta Incorporated 20 Boehringer Ingelheim GmbH 21 Bristol-Myers Squibb Company 22 Eisai Co., Ltd. 23 Hansa Medical AB 24 Immunomedics, Inc. 25 Intas Pharmaceuticals Ltd. 26 Jiangsu Hengrui Medicine Co., Ltd. 27 Merck & Co., Inc. 28 Momenta Pharmaceuticals, Inc. 29 Novartis AG 30 Pfizer Inc. 31 PhytoHealth Corporation 32 Protalex, Inc. 33 Rigel Pharmaceuticals, Inc. 34 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Target 36 Assessment by Mechanism of Action 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 avatrombopag - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 BI-655064 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 BMS-986004 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 eltrombopag olamine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 eltrombopag olamine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 fostamatinib disodium - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 GL-2045 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 GSK-2285921 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Hetrombopag Olamine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 MK-8723 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 PBF-1509 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 PHN-013 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PRTX-100 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 romiplostim - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 romiplostim biosimilar - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 SM-101 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 thrombopoietin - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 veltuzumab - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Recent Pipeline Updates 78 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 93 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 94 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 95 Featured News & Press Releases 95 Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 95 Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 95 Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 96 Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 97 Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 97 Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 98 Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 99 Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 99 Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 99 Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 100 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102
List of Tables
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H1 2016 18 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H1 2016 19 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Baxalta Incorporated, H1 2016 20 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 21 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H1 2016 22 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Eisai Co., Ltd., H1 2016 23 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H1 2016 24 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H1 2016 25 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 26 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 27 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H1 2016 28 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 29 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H1 2016 30 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H1 2016 31 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H1 2016 32 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H1 2016 33 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 34 Assessment by Monotherapy Products, H1 2016 35 Number of Products by Stage and Target, H1 2016 37 Number of Products by Stage and Mechanism of Action, H1 2016 39 Number of Products by Stage and Route of Administration, H1 2016 41 Number of Products by Stage and Molecule Type, H1 2016 43 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics - Recent Pipeline Updates, H1 2016 78 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H1 2016 93 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H1 2016 94


List of Figures
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 35 Number of Products by Top 10 Targets, H1 2016 36 Number of Products by Stage and Top 10 Targets, H1 2016 36 Number of Products by Top 10 Mechanism of Actions, H1 2016 38 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 38 Number of Products by Routes of Administration, H1 2016 40 Number of Products by Stage and Routes of Administration, H1 2016 40 Number of Products by Molecule Types, H1 2016 42 Number of Products by Stage and Molecule Types, H1 2016 42

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify